Back to History Current Version

Promoting COVID-19 vaccination in India

Last registered on June 26, 2022
View Trial History

Pre-Trial

Trial Information

General Information

Title
Promoting COVID-19 vaccination in India
RCT ID
AEARCTR-0008599
Initial registration date
June 22, 2022

Initial registration date is when the trial was registered.

It corresponds to when the registration was submitted to the Registry to be reviewed for publication.

First published
June 26, 2022, 5:22 AM EDT

First published corresponds to when the trial was first made public on the Registry after being reviewed.

Locations

There is information in this trial unavailable to the public. Use the button below to request access.

Request Information

Primary Investigator

Name
Debayan Pakrashi
Affiliation
Department of Economic Sciences, Indian Institute of Technology Kanpur
Contact Primary Investigator

Other Primary Investigator(s)

PI Name
Asadul Islam
PI Affiliation
Monash University
Contact Investigator
PI Name
Hyuncheol Kim
PI Affiliation
Hong Kong University of Science and Technology
Contact Investigator
PI Name
Sonalini Khetrapal
PI Affiliation
Asian Development Bank
Contact Investigator
PI Name
Armand Sim
PI Affiliation
Monash University
Contact Investigator

Additional Trial Information

Status
In development
Start date
2021-11-01
End date
2024-12-31
Keywords
Behavior, Governance, Health, Welfare
Additional Keywords
vaccine hesitancy, public health, incentives, accessibility, awareness
JEL code(s)
I1, I12, I18, I20, I3
Secondary IDs
Prior work
This trial does not extend or rely on any prior RCTs.
Abstract
Using a RCT design, we will attempt to understand the issue of vaccine hesitancy in India and understand whether awareness campaign about the benefits associated with vaccination, non-financial incentives provided via a sure gift or lucky draw gift payment (both conditional upon acceptance), making vaccine more accessible or communication intervention to address misconception by eminent figures in the community reduce vaccine hesitancy and lead to widespread vaccination using the government funded free vaccines. Therefore, the objective of this study is to understand the barriers to vaccine take-up and identify the most effective way to increase it.
External Link(s)

Registration Citation

Citation
Islam, Asadul et al. 2022. "Promoting COVID-19 vaccination in India." AEA RCT Registry. June 26. https://doi.org/10.1257/rct.8599-1.0
Sponsors & Partners

There is information in this trial unavailable to the public. Use the button below to request access.

Request Information
Experimental Details

Interventions

Intervention(s)
To isolate the effect of each of the different interventions (non-financial incentive (gifts) vis-à-vis accessibility vis-à-vis campaign or communication intervention to address misconception) on willingness to take vaccines and actually getting vaccinated, we will randomly assign about 8,000 individuals aged 18-65 years (one from each household) randomly selected from about 884 different locations (both rural and urban) across three different districts (Mahoba, Farrukabad and Sitapur) in Uttar Pradesh to one of the five treatments and one control group. The choice of Uttar Pradesh as the research locale is justified by the wide prevalence of hesitancy to get vaccinated despite availability in the state.
Intervention Start Date
2022-07-01
Intervention End Date
2022-08-15

Primary Outcomes

Primary Outcomes (end points)
Knowledge about COVID-19 and vaccines, beliefs about COVID-19 and vaccines, vaccination intention and uptake.
Primary Outcomes (explanation)

Secondary Outcomes

Secondary Outcomes (end points)
Fear of COVID infection, compliance behaviors related to COVID-19 such as mask wearing, susceptibility to post-intervention COVID-19 infection.
Secondary Outcomes (explanation)

Experimental Design

Experimental Design
We will select a total of about 884 different locations of different sizes (both rural and urban) across several districts in India and on average about 9 individuals (one individual from each household) from each of these locations for the study. Randomization into treatment and control groups will be done next also at the location level. There will be five treatment and one control group.
Experimental Design Details
Not available
Randomization Method
The 8,000 eligible households identified from about 884 regions will be randomised at the location level (using STATA on the office computer). From each household, we will focus on adult individuals who are eligible for Covid19 vaccine free of cost, yet unvaccinated at the time of listing and intervention.
Randomization Unit
Location level.
Was the treatment clustered?
Yes

Experiment Characteristics

Sample size: planned number of clusters
884 locations (from both rural and urban regions).
Sample size: planned number of observations
About 8,000 individuals (one from each household).
Sample size (or number of clusters) by treatment arms
About 8,000 selected individuals identified from the 884 locations will be randomised (using a computer program), with 295 locations in the pure control (T0), 103 in information campaign only (T1) arm, 124 locations in T2, 133 locations in T3, 118 locations in T4 and 111 locations in the T5 arm.
Minimum detectable effect size for main outcomes (accounting for sample design and clustering)
Supporting Documents and Materials
IRB

Institutional Review Boards (IRBs)

IRB Name
Indian Institute of Technology Kanpur
IRB Approval Date
2021-09-02
IRB Approval Number
IITK/IEC/2021-22/I/14
Analysis Plan